EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Management of latent tuberculosis infection in patients with kidney disease

Wiwat Chancharoenthana iD, Tanaya Siripoon, Supitcha Kamolratanakul, Viravarn Luvira, Weerapong Phumratanaprapin, Marcus J Schultz, Claudio Ronco, Punnee Pitisuttithum iD

Clinical Microbiology Reviews · 11.06.2026 · 39 (2)

DOI: 10.1128/cmr.00353-25 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Microbiology Reviews, erschienen am 11.06.2026. Verfasst von Wiwat Chancharoenthana und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Latent Tuberculosis, Antitubercular Agents, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Council Research of Thailand and Mahidol University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Latent tuberculosis infection (LTBI) is common and preventable among patients with chronic kidney disease (CKD), where uremia and iatrogenic immunosuppression heighten reactivation risk. This narrative review synthesizes evidence across pre-dialysis CKD, dialysis, and kidney transplantation to propose a pragmatic care pathway. In advanced CKD, the tuberculin skin test performs poorly, whereas interferon-γ release assays (IGRAs) are preferred. Screening should be risk-targeted in pre-dialysis CKD, systematic at dialysis initiation, and mandatory pre-transplant for candidates and living donors. Following a positive test, clinicians must exclude active tuberculosis via clinical assessment and chest imaging before starting preventive therapy. Short-course rifamycin-based regimens (4 months of daily rifampin [4R], 3 months of once‑weekly isoniazid plus rifapentine [3HP], or 3 months of daily isoniazid plus rifampin [3HR]) enhance completion rates compared with 9 months of daily isoniazid (9H). In transplant recipients, rifamycin interactions with calcineurin and Mammalian target of rapamycin (mTOR) inhibitors typically favor 9H; rifamycins demand expert multidisciplinary management with intensive therapeutic drug monitoring. Programmatic data from dialysis units show high completion with tolerable toxicity, affirming routine feasibility. We integrate IGRA-based screening at critical transitions with tailored regimen selection, pyridoxine coadministration for isoniazid, and structured safety monitoring. Priorities include validating novel Mycobacterium tuberculosis antigen-based skin tests in CKD and developing implementation strategies to standardize renal care. We delineate setting-specific approaches for high- versus low-burden countries, addressing subclinical and incipient TB challenges in high-burden contexts. Adopting this framework can curb active TB progression, safeguard grafts, and enhance patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Latent TuberculosisAntitubercular AgentsRenal Insufficiency, ChronicHumansKidney TransplantationIsoniazidTuberculin TestDisease ManagementRifampin

Stichwörter der Autor:innen

chronic kidney diseasehemodialysisimmunosuppressioninterferon γ release assayskidney transplantationlatent tuberculosis infectionrifamycin based regimens

Substanzen

Antitubercular AgentsIsoniazidRifampin

Autor:innen und Institutionen

  • Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • Tropical Immunology and Translational Research Unit (TITRU), Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • Department of Intensive Care, Laboratory of Experimental Intensive Care and Anesthesiology (L·E·I·C·A), Amsterdam University Medical Centers, Location 'AMC', Amsterdam, the Netherlands.
  • Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom.
  • Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

ORCID-Profile: Wiwat Chancharoenthana, Punnee Pitisuttithum

Förderung

  • National Council Research of Thailand and Mahidol University

Zitieren

APA

Chancharoenthana, W., Siripoon, T., Kamolratanakul, S., Luvira, V., Phumratanaprapin, W., Schultz, M. J., Ronco, C., & Pitisuttithum, P. (2026). Management of latent tuberculosis infection in patients with kidney disease. Clinical Microbiology Reviews, 39(2). https://doi.org/10.1128/cmr.00353-25

Vancouver

Chancharoenthana W, Siripoon T, Kamolratanakul S, Luvira V, Phumratanaprapin W, Schultz MJ, et al. Management of latent tuberculosis infection in patients with kidney disease. Clinical Microbiology Reviews. 2026;39(2). doi:10.1128/cmr.00353-25

BibTeX
@article{Chancharoenthana2026,
  author = {Chancharoenthana, Wiwat and Siripoon, Tanaya and Kamolratanakul, Supitcha and Luvira, Viravarn and Phumratanaprapin, Weerapong and Schultz, Marcus J and Ronco, Claudio and Pitisuttithum, Punnee},
  title = {Management of latent tuberculosis infection in patients with kidney disease},
  journal = {Clinical Microbiology Reviews},
  year = {2026},
  volume = {39},
  number = {2},
  doi = {10.1128/cmr.00353-25}
}
Kostenlos starten →